Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular Disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cozzolino M, Galassi A, Pivari F, Ciceri P, Conte F. The Cardiovascular Burden in End-Stage Renal Disease. Contrib Nephrol. 2017;191:44–57.

Article  PubMed  Google Scholar 

House AA, Wanner C, Sarnak MJ, Pina IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(6):1304–17.

Article  PubMed  Google Scholar 

USE. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2020.

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with Cardiovascular and kidney outcomes in patients with type 2 diabetes: a Meta-analysis. JAMA Cardiol. 2021;6(2):148–58.

Article  PubMed  Google Scholar 

Odutayo A, da Costa BR, Pereira TV, Garg V, Iskander S, Roble F, et al. Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and Cardiovascular outcomes in adults with type 2 diabetes: a bayesian Meta-analysis and Meta-regression. J Am Heart Assoc. 2021;10(18):e019918.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kidney Disease. Improving global outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–314.

Google Scholar 

Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin Heart Failure: Diuret Cardiorenal Eff Circulation. 2020;142(11):1028–39.

CAS  Google Scholar 

Thomson SC, Vallon V. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats. Am J Physiol Ren Physiol. 2021;320(5):F761–71.

Article  CAS  Google Scholar 

Center for Drug Evaluation and Research. Approval Package for APPLICATION NUMBER 202293Orig1s026. 2023 [ https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/202293Orig1s026.pdf

Center for Drug Evaluation and Research. SUPPLEMENT APPROVAL for NDA 204042/S-040. 2023 [ https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204042Orig1s040ltr.pdf

Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose Cotransport-2 inhibitors on blood pressure in people with type 2 diabetes Mellitus: a systematic review and Meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc. 2017;6(6).

Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, et al. Effects of Sodium/Glucose cotransporter 2 (SGLT2) inhibitors on Cardiovascular and metabolic outcomes in patients without diabetes Mellitus: a systematic review and Meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):e019463.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of Hyperkalemia in people with type 2 diabetes: a Meta-analysis of individual Participant Data from Randomized, controlled trials. Circulation. 2022;145(19):1460–70.

Article  CAS  PubMed  Google Scholar 

Luo X, Xu J, Zhou S, Xue C, Chen Z, Mao Z. Influence of SGLT2i and RAASi and their combination on risk of Hyperkalemia in DKD: A Network Meta-Analysis. Clin J Am Soc Nephrol. 2023;18(8):1019–30.

Article  PubMed  Google Scholar 

Liu X, Chen Y, Liu T, Cai L, Yang X, Mou C. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023;14:1115321.

Article  PubMed  Google Scholar 

Wang X, Wu N, Sun C, Jin D, Lu H. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2023;15(1):113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2023:117236.

Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2).

Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suijk DLS, van Baar MJB, van Bommel EJM, Iqbal Z, Krebber MM, Vallon V, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022;17(5):663–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCormick N, Yokose C, Wei J, Lu N, Wexler DJ, Avina-Zubieta JA, et al. Comparative effectiveness of sodium-glucose Cotransporter-2 inhibitors for recurrent gout flares and gout-primary Emergency Department visits and hospitalizations: a General Population Cohort Study. Ann Intern Med. 2023;176(8):1067–80.

Article  PubMed  Google Scholar 

Balasubramanian P, Wanner C, Ferreira JP, Ofstad AP, Elsaesser A, Zinman B, Inzucchi SE. Empagliflozin and decreased risk of Nephrolithiasis: a potential New Role for SGLT2 inhibition? J Clin Endocrinol Metab. 2022;107(7):e3003–7.

Article  PubMed  PubMed Central  Google Scholar 

Paik JM, Tesfaye H, Curhan GC, Zakoul H, Wexler DJ, Patorno E. Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. JAMA Intern Med. 2024;184(3):265–74.

Article  CAS  PubMed  Google Scholar 

Harmacek D, Pruijm M, Burnier M, Muller ME, Ghajarzadeh-Wurzner A, Bonny O, Zanchi A. Empagliflozin Changes urine supersaturation by decreasing pH and increasing citrate. J Am Soc Nephrol. 2022;33(6):1073–5.

Article  PubMed  PubMed Central  Google Scholar 

Bletsa E, Filippas-Dekouan S, Kostara C, Dafopoulos P, Dimou A, Pappa E, et al. Effect of Dapagliflozin on urine metabolome in patients with type 2 diabetes. J Clin Endocrinol Metab. 2021;106(5):1269–83.

Article  PubMed  PubMed Central  Google Scholar 

Packer M. Alleviation of Anemia by SGLT2 inhibitors in patients with CKD: mechanisms and results of long-term placebo-controlled trials. Clin J Am Soc Nephrol. 2023.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

Article  CAS  PubMed  Google Scholar 

Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and kidney benefits of Empagliflozin in Heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143(4):310–21.

Article  CAS  PubMed  Google Scholar 

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized Trial of Empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55.

Article  CAS  PubMed  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

Article  CAS  PubMed  Google Scholar 

Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, et al. Cardiac and Metabolic effects of Dapagliflozin in Heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834–44.

Article  CAS  PubMed  Google Scholar 

Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. Association of SGLT2 inhibitors with risk of Atrial Fibrillation and Stroke in patients with and without type 2 diabetes: a systemic review and Meta-analysis of Randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(2):e145–52.

Article  CAS  PubMed  Google Scholar 

Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium-glucose co-transpor